Innovative Research Award

Andre Lieber
University of Washington,United States

Andre Lieber
Affiliation	University of Washington
Country	United States
Google Scholar ID	KA5seSwAAAAJ
Documents	456
Citations	17,141
h-index	72
Subject Area	Biochemistry, Genetics and Molecular Biology
Event	International Academic Excellence Awards

Andre Lieber is a researcher at the University of Washington whose documented scholarly work focuses substantially on adenovirus biology, viral vectors, host–virus interactions, and gene-transfer technologies. The supplied profile reports 456 documents, 17,141 citations, and an h-index of 72. His publication record includes highly cited studies addressing adenoviral receptors, vector tropism, liver toxicity, and gene transfer into hematopoietic cells.

Abstract

Lieber’s research profile is centered on molecular and translational aspects of adenovirus biology. His publications examine how adenoviruses recognize cellular receptors, enter specific cell populations, interact with blood factors, and can be engineered for gene delivery. These studies connect fundamental virology with the development and evaluation of viral-vector technologies.

Keywords

Adenovirus; gene therapy; viral vectors; CD46; desmoglein 2; gene transfer; hematopoietic cells; liver toxicity; molecular biology; virology.

Introduction

Lieber’s published work at the University of Washington includes investigations into adenoviral receptors and vector behavior. A 2003 Nature Medicine study identified CD46 as a cellular receptor used by most group B adenoviruses, providing insight into adenovirus attachment and infection mechanisms. [1] Subsequent research examined additional receptor pathways and systemic interactions relevant to adenoviral vectors.

Research Profile

The supplied publication record indicates several interconnected research themes:

• Adenovirus receptors and mechanisms of cellular entry.
• Engineering and retargeting of adenoviral vectors for gene transfer.
• Host–virus interactions involving blood factors and hepatic tissues.
• Viral-vector tropism and therapeutic applications.

Research Contributions

Research associated with Lieber has contributed to understanding receptor-mediated adenovirus infection. Work on desmoglein 2 identified it as a receptor for adenovirus serotypes 3, 7, 11, and 14. [2] Another study demonstrated that blood factors can influence adenoviral targeting of liver cells and associated toxicity following systemic administration. [3] Earlier vector research investigated efficient gene transfer into human CD34+ cells using a retargeted adenovirus vector. [4]

Publications

• CD46 is a cellular receptor for group B adenoviruses (2003), Nature Medicine 9(11), 1408–1412; 1,044 citations in the supplied record. [1]
• Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14 (2011), Nature Medicine 17(1), 96–104; 567 citations. [2]
• Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity (2005), Journal of Virology 79(12), 7478–7491; 528 citations. [3]
• The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors (1997), Journal of Virology 71(11), 8798–8807; 522 citations. [5]
• Efficient Gene Transfer into Human CD34+ Cells by a Retargeted Adenovirus Vector (2000), Journal of Virology 74(6), 2567–2583; 489 citations. [4]

Research Impact

The supplied citation record indicates substantial scholarly attention to Lieber’s adenovirus research. The five listed publications collectively account for thousands of citations in the provided Google Scholar data, with the CD46 receptor study recording 1,044 citations. Citation counts are database-dependent and may change over time; the figures presented here should therefore be regarded as a supplied bibliometric snapshot.

Award Suitability

For the stated International Academic Excellence Awards, the documented record provides measurable indicators of sustained scholarly activity, including 456 reported documents, 17,141 citations, and an h-index of 72. The publication examples also demonstrate research spanning fundamental virology, molecular receptor biology, and gene-transfer technologies. Eligibility and final recognition remain subject to the official criteria and assessment procedures of the awarding organization.

Conclusion

Andre Lieber’s documented research profile reflects sustained contributions to adenovirus biology and viral-vector research. His publications address receptor identification, cellular tropism, systemic vector interactions, toxicity, and gene-transfer strategies. The supplied bibliometric figures and publication record provide a factual basis for documenting his academic profile in connection with the International Academic Excellence Awards.

External Links

• Google Scholar Profile
• International Academic Excellence Awards Website

References

1. Gaggar, A.; Shayakhmetov, D.M.; Lieber, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nature Medicine, 9(11), 1408–1412. DOI: https://doi.org/10.1038/nm952
2. Wang, H.; Li, Z.Y.; Liu, Y.; et al. (2011). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nature Medicine, 17(1), 96–104. DOI: https://doi.org/10.1038/nm.2270
3. Shayakhmetov, D.M.; Gaggar, A.; Ni, S.; Li, Z.Y.; Lieber, A. (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. Journal of Virology, 79(12), 7478–7491. DOI: https://doi.org/10.1128/JVI.79.12.7478-7491.2005
4. Shayakhmetov, D.M.; Papayannopoulou, T.; Stamatoyannopoulos, G.; Lieber, A. (2000). Efficient Gene Transfer into Human CD34+ Cells by a Retargeted Adenovirus Vector. Journal of Virology, 74(6), 2567–2583. DOI: https://doi.org/10.1128/jvi.74.6.2567-2583.2000
5. Lieber, A.; He, C.Y.; Meuse, L.; Schowalter, D.; Kirillova, I.; Winther, B.; Kay, M.A. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Journal of Virology, 71(11), 8798–8807.